Scarica l'app Stockscreener
13.31
4.04%
-0.56
Dopo l'orario di chiusura:
13.37
0.06
+0.45%
Precedente Chiudi:
$13.87
Aprire:
$14.15
Volume 24 ore:
4.86M
Relative Volume:
1.00
Capitalizzazione di mercato:
$1.58B
Reddito:
$67.67M
Utile/perdita netta:
$-412.69M
Rapporto P/E:
-3.4783
EPS:
-3.8266
Flusso di cassa netto:
$-395.87M
1 W Prestazione:
+0.83%
1M Prestazione:
+1.37%
6M Prestazione:
-1.92%
1 anno Prestazione:
+57.70%
Intervallo 1D:
$13.20
$14.33
Intervallo di 1 settimana:
$11.76
$14.33
Portata 52W:
$6.83
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
13.31 | 1.65B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying - Barchart
Intellia Therapeutics Announces Investor Conference Participation on May 5, 2026 - geneonline.com
Three Intellia fireside chats will stream live through June 3 - Stock Titan
Intellia Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi - The National Law Review
ARK Invest Increases Stake in Intellia Therapeutics (NTLA) Amid Sector Rotation - GuruFocus
Intellia Therapeutics says its CRISPR-based treatment succeeds in pivotal trial - MSN
Lonvo-z gene-editing therapy lowers HAE attacks by 87% in Phase 3 trial - Angioedema News
Intellia Initiates Rolling BLA Submission For In Vivo CRISPR Therapy In Hereditary Angioedema - marketscreener.com
NTLA stock rises 20% in 3 months: Here's what you should know - MSN
Behavioral Patterns of NTLA and Institutional Flows - Stock Traders Daily
Intellia Therapeutics shares slip despite strong phase 3 data - MSN
symbol__ Stock Quote Price and Forecast - CNN
NTLA jumps premarket on positive late-stage trial data for gene-editing therapy — retail says buy now before it’s too late - MSN
Intellia Therapeutics, Inc. Sued for Securities Law Violations - GuruFocus
Intellia Therapeutics (NTLA) Sees Major Purchase by ARK Investme - GuruFocus
Cathie Wood’s ARK sells AMD stock, buys Roblox and Intellia - Investing.com
Intellia Therapeutics Prices Public Equity Offering to Fund Pipeline - The Globe and Mail
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
43 new Intellia employees get stock awards worth 208,850 shares - Stock Titan
Intellia Therapeutics prices $180M stock offering at discount - MSN
Intellia Therapeutics | DEF 14A: Definitive information statements - Moomoo
Intellia Therapeutics (NTLA) Is Down 15.1% After Phase 3 lonvo-z Data And $180M Equity RaiseHas The Bull Case Changed? - Yahoo Finance
Intellia Therapeutics | SCHEDULE 13G: Others - Moomoo
Intellia (NASDAQ: NTLA) equity sale boosts cash runway into 2028 - Stock Titan
Intellia Therapeutics (NASDAQ: NTLA) sets 2026 virtual meeting on directors, pay and auditor - Stock Titan
MSN Money - MSN
NTLA Stock Draws Bulls After Phase 3 Gene-Editing Win - StocksToTrade
[ARS] Intellia Therapeutics, Inc. SEC Filing - Stock Titan
Vanguard (NTLA) files Schedule 13G reporting 5.03% ownership (5.95M) - Stock Titan
Intellia Therapeutics | 424B5: Prospectus - Moomoo
NTLA Forecast, Price Target & Analyst Ratings | INTELLIA THERAPEUTICS INC (NASDAQ:NTLA) - ChartMill
ARK Investment Acquires 2.4 Million Shares of Intellia Therapeutics (NTLA) - GuruFocus
$Intellia Therapeutics (NTLA.US)$ Hope u will give me good profit starr from today - Moomoo
Intellia Therapeutics (NASDAQ: NTLA) offers 16.7M shares at $10.75 - Stock Titan
NTLA Stock Slides As $150M Offering Signals Dilution Risk - timothysykes.com
Vanguard Portfolio Management holds 5.3% of Intellia (NASDAQ: NTLA) - Stock Titan
Intellia Therapeutics earnings in focus after gene editing breakthrough By Investing.com - Investing.com South Africa
Intellia Therapeutics earnings in focus after gene editing breakthrough - Investing.com UK
NTLA Stock Pressured As $150M Offering Tests Trader Nerves - StocksToTrade
NTLA Secures $180 Million in Increased Common Stock Offering - GuruFocus
Intellia Therapeutics (NTLA) Launches $180M Public Offering Amid Share Price Drop - GuruFocus
Intellia Therapeutics stock tumbles on discounted offering - Investing.com
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Intellia Therapeutics (NTLA) and Incyte (INCY) - The Globe and Mail
NTLA Stock Slips As $150M Equity Offering Raises Dilution Fears - timothysykes.com
Intellia Files BLA After Lonvo-z Meets Phase 3 Endpoints - CRISPR Medicine News
Intellia Therapeutics stock tumbles on discounted offering By Investing.com - Investing.com India
Intellia Therapeutics stock tumbles on dilutive offering By Investing.com - Investing.com Canada
Intellia Therapeutics stock tumbles on dilutive offering - Investing.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA), Biogen (BIIB) and HCA Healthcare (HCA) - The Globe and Mail
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock - The Manila Times
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):